QCQi Cai

Qi Cai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qi Cai has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnosis and Management of Sarcoidosis-like Reaction in Adjuvant Immunotherapy: A Comprehensive Review and Clinical Implications

    by Matthew Lee, Qi Cai, Jue Wang

    Immune checkpoint inhibitors (ICIs) have transformed oncologic care and are increasingly used as adjuvant therapy to reduce the risk of recurrence. However, this shift has introduced immune-related adverse events (irAEs) to patients who may otherwise be clinically disease-free after definitive therapy. Sarcoidosis-like reaction (SLR) is an uncommon but important irAE characterized by non-necrotizing granulomatous inflammation. In the adjuvant setting, SLR is uniquely consequential because it can closely mimic recurrent malignancy on surveillance imaging and thereby prompt unnecessary diagnostic procedures, treatment interruption, or escalation of care. This review summarizes the current evidence on ICI-associated SLR with an emphasis on adjuvant immunotherapy, where practical guidance remains limited. We integrate evidence from clinical trials, real-world cohorts, and published case series to summarize the reported incidence of SLR, proposed immunologic mechanisms, clinical and radiographic presentation, pathology, differential diagnosis, and management. Particular attention is given to the problem of distinguishing SLR from recurrence, when tissue confirmation should be prioritized, and how management should be individualized according to clinical severity and organ involvement. Common radiographic features include bilateral mediastinal and hilar lymphadenopathy and pulmonary nodules, but tissue confirmation remains the diagnostic gold standard when feasible. Many cases are low grade and may be managed conservatively. Greater recognition of ICI-associated SLR is critical to avoid misdiagnosis and unnecessary escalation of care while preserving the therapeutic benefit of adjuvant immunotherapy.


  • Non-syndromic Multifocal Low-Grade Oncocytic Renal Tumors, Including Microtumors, in End-Stage Renal Disease Kidneys with Synchronous Non-TSC Renal Cell Neoplasms

    by Qi Cai, Liwei Jia, Jyoti Balani, Payal Kapur

    Low-grade oncocytic tumor (LOT) is a recently described indolent renal neoplasm with over 80% of tumors harboring mutations in the TSC/MTOR signaling pathway. Typically, LOTs present as sporadic solitary tumors in patients with normal renal function, and occasionally in patients with end-stage kidney disease. However, multifocal LOTs have rarely been observed in patients with tuberous sclerosis complex (TSC). We report four patients with multifocal LOTs, including microtumors, coexisting with other renal cell neoplasms in the context of chronic kidney disease (CKD) or end stage renal disease (ESRD) in the absence of clinical features of TSC. Notably, one patient had bilateral, multifocal LOTs alongside synchronous acquired cystic disease-associated renal cell carcinoma (ACD-RCC); while two other patients had concurrent clear cell papillary renal cell tumor (CCPRCT), one with multifocal and the other with solitary LOT; the remaining patient had both coexisting CCPRCT and ACD-RCC as well as multifocal LOT. This series highlights that multifocal LOTs, including microtumors, can be seen in the setting of ESRD and can arise independently of hereditary TSC. The co-occurrence with other ESRD-associated neoplasms underscores the need for broader recognition of LOT within this clinical context.

  • Open Access

    Belzutifan and Transarterial Embolization for Symptomatic Vaginal Metastasis from Renal Cell Carcinoma: A Case Report

    by Sarah Attia, Zane N. Gray, Qi Cai, Sanjeeva P. Kalva, Moaz M. Choudhary, Jue Wang

    Renal cell carcinoma (RCC) rarely metastasizes to the vagina, with approximately 80 cases reported, and no established treatment guidelines exist for management. We report a case of a 57-year-old woman with heavily pretreated, metastatic clear cell RCC who developed a symptomatic vaginal metastasis refractory to multiple systemic therapies and palliative radiation. She achieved complete clinical remission and significant radiographic regression following a novel combination of belzutifan (hypoxia-inducible factor 2 alpha inhibitor) and transarterial embolization, both well tolerated. This is the first documented case of this combined approach for RCC vaginal metastasis, suggesting a promising therapeutic strategy for managing rare, refractory metastatic sites.


  • Determinants of late metastases in renal cell carcinoma

    by Payal Kapur, Hua Zhong, Alana Christie, Haitao Xu, Qi Cai, Ellen Araj, David Kim, Jeffrey Miyata, Vanina T Tcheuyap, Colleen T Ball, et al.

    Background: The mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. Methods: This study evaluated 2 large independent cohorts for differences in tumor biology between patients who developed metastases early (≤1 year after nephrectomy) and those with late onset (>3 years). Results: In the discovery cohort (n = 161), late metastatic RCC was associated with clear cell histology (88.9% vs 78.7%), lower pathological stage (pT1-2; 40.3% vs 18.0%), and favorable histopathological features including low grade (40.0% vs 2.3%), less sarcomatoid (5.6% vs 21.8%), and reduced necrosis (37.7% vs 78.3%; all P < .02). Late metastatic RCC tumors exhibited increased angiogenesis (63.5% vs 19.4%) and reduced inflammation (78.8% vs 50.0%; all P < .02) profiles. Genomic driver analyses revealed comparable rates of PBRM1 and SETD2 loss in late and early metastatic RCC, while BAP1 loss was significantly less common in late metastatic RCC (7.5% vs 27.1%; P < .02). In multivariable models, BAP1/PBRM1/SETD2 status and tumor necrosis emerged as key discriminators of late metastatic RCCs. These findings were confirmed in the second cohort (n = 307). Late metastatic RCC was enriched for fatty acid oxidation and angiogenesis pathways, supporting a less aggressive phenotype. This was further evidenced by a lower engraftment rate in murine models (0% vs 36.5%; P < .001) and significantly longer overall survival from the time of metastasis (median survival doubled, P < .001). Interestingly, late metastatic RCC shared genomic and phenotypic features with RCC that metastasizes to the pancreas, suggesting a common underlying biology influencing both metastatic latency and pancreatic tropism. Conclusions: Overall, these findings advocate for recognition of late metastatic RCC because of its distinct biology and improved prognosis.


  • Multicystic Clear Cell Renal Tumors With Low-grade Nuclear Features: Time to Include TFE3 Translocation-associated Carcinomas

    by Qi Cai, Jeffrey Gagan, Prasad Koduru, Jeffrey Cadeddu, Rajal B. Shah, Payal Kapur, Doreen N. Palsgrove

    TFE3-rearranged renal cell carcinoma (RCC) is a distinct, uncommon entity with more than 20 different fusion partners identified; however, histomorphology may be suggestive of specific fusion partners in select TFE3-rearranged RCCs. For example, most MED15::TFE3 fusion associated RCCs exhibit multilocular cystic morphology, mimicking multilocular cystic renal neoplasm of low malignant potential. Here we present a case of MED15::TFE3 RCC in an older adult and review the literature with an emphasis on practical diagnostic approaches for predominantly cystic, low-grade, clear cell renal tumors.


  • Open Access

    Clinicopathological and molecular genetic analysis of 4 typical Chinese HNPCC families

    by Qi Cai, Meng-Hong Sun, Hong-Fen Lu, Tai-Ming Zhang, Shan-Jing Mo, Ye Xu, San-Jun Cai, Xiong-Zeng Zhu, Da-Ren Shi

    Clinicopathological and molecular genetic analysis of 4 typical Chinese HNPCC families